visit to visit variation. In this article, we analyze the relationship between mean on-treatment SBP, SBP-variation, mean on-treatment HR, and HR-variation and cognitive decline (≥5 points reduction in the mini mental state examination [MMSE] ) and cognitive dysfunction defined as a score of ≤24 points indicative of clinically relevant cognitive impairment. Cognitive deterioration was defined as reduction of ≥1 point per year or decline to ≤24 points). The latter end point is sensitive to the absolute level of MMSE and to changes over time although accounting for different durations of follow-up. We used the pooled data set of the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET) and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease (TRANSCEND).
17,18

Methods
Studied Patients
The primary objective and protocol of the ONTARGET and TRANSCEND trials have been described in detail previously. 17, 18 In brief, patients age ≥55 years without symptomatic heart failure at entry and with a history of coronary artery disease, peripheral artery disease, prior TIA or stroke or diabetes mellitus complicated by organ damage were eligible for inclusion in the studies. In ONTARGET patients known to be tolerant to ACE inhibitors were randomly assigned to ramipril 10 mg qd, telmisartan 80 mg qd, or the combination thereof (double-dummy design), whereas in TRANSCEND patients intolerant to ACE inhibitors were randomized to telmisartan 80 mg qd or matching placebo. Study medication was given on top of preexisting treatment used by the treating physicians and investigators. The other medications were given according to best clinical practice in the individual study centers. Investigators were advised to maintain preexisting blood pressure medications targeting blood pressures of <130/80 mm Hg for patients with chronic kidney disease and 140/90 mm Hg in the other individuals. Patients with ontreatment blood pressure >160/100 mm Hg at entry were not eligible. 17, 18 Visits were scheduled at 6 weeks and 6 months after randomization and every 6 months thereafter. In ONTARGET, 25.620 patients from 733 centers in 40 countries were randomized, whereas in TRANSCEND, 5926 patients from a subset of 630 centers were randomized. The median follow-up period in both studies was 56 months. The protocol procedures and main results of ONTARGET and TRANSCEND have been published previously 17, 18 showing comparable outcomes in the composite of cardiovascular death, myocardial infarction, stroke, or hospitalization for heart failure (time to first event) in the 3 active treatment arms of ONTARGET and a lower event rate in the telmisartan group of TRANSCEND which, however, was not significant.
The primary objective of this analysis was to evaluate the association of in-trial mean SBP, visit to visit SBP variation, mean HR, and visit to visit HR variation with cognitive decline and incident cognitive dysfunction in high risk cardiovascular patients. At each visit in both studies, resting blood pressure and HR was measured in duplicate in sitting position after 3 minutes of rest using an automated validated device (Omron, model HEM 757; Omron corporation, Kyoto, Japan). In-trial blood pressure and HR were averaged using mean measurements at each individual visit. Visit to visit variation of BP and HR was calculated as coefficient of variation (CV), that is, the ratio of standard deviation (SD) and mean (CV=SD/ mean×100%). Measurements from all visits (including baseline values) before the final MMSE were included, and ≥3 visits with data were required for inclusion in the analysis. The studies were approved by the local ethics committees in accordance with the Declaration of Helsinki.
Cognitive function was evaluated in all patients by MMSE. The score ranges from 0 to 30 with lower scores indicative of greater degree of cognitive impairment. MMSE was done at baseline, after 2 years and at the penultimate visit (usually between 3 and 5 years). The majority of patients were evaluated at 3 to 5.5 years (88.5%), and in only 11.5% of patients, the 2-year MMSE was the last evaluation. In line with a previous report, 15 cognitive dysfunction was defined as MMSE ≤24 points at the last available visit (2 years or penultimate), and cognitive decline was defined as ≥5 points decrease of MMSE. The MMSE and its changes are related to future dementia, although its accuracy in the diagnosis of dementia is weak. 19, 20 It has been widely used to determine cognitive changes over time and is a feasible instrument in large clinical trials. [21] [22] [23] [24] Sensitivity analyses pointed out that changes between 3 and 4 points decline might reliably reflect a significant cognitive decline. 22, 23 To overcome these uncertainties, we present a ≥5 point MMSE decline as indication for a significant cognitive decline. Similar results were obtained when a cutoff of 2 points was evaluated. To account for different follow-up periods, in the combined outcome of cognitive deterioration, a decline in ≥1 MMSE points per year or a reduction to ≤24 points was also evaluated.
The different treatment arms of ONTARGET and TRANSCEND did not show any differences in cognitive function at baseline. 24 To explore the role of mean SBP, SBP-CV, mean HR, and HR-CV on cognitive function, data of enrolled patients without cognitive dysfunction at baseline (MMSE >24 points) and ≥1 available follow-up score was included in this analysis.
31 546 patients were enrolled in ONTARGET or TRANSCEND. In 4166 patients, there was preexisting significant cognitive dysfunction (MMSE ≤24) or no MMSE score at baseline was available. In further 2646 patients, no follow-up MMSE was available; in an additional 42 patients, <3 visits were available for the calculation of SBP/ HR mean and variation, and in further 99 patients, data for important covariates (those to be used in model building) were missing. Thus, 24 593 patients remained in the present analysis ( Figure 1 ). On average, SBP and HR measurements were available from 10.7±2.2 visits (range 3-13) over an observation period of 53.1±11.5 months.
Statistical Analysis
Patients were subdivided in quintiles based on their mean SBP, SBP-CV, mean HR, and HR-CV, allowing cohort statistical evaluations with adequate group sizes. Baseline characteristics were presented for quintiles, continuous data as means±standard deviations, and categorical data as percentages. Quintiles were tested for differences using ANOVA for continuous data and the χ 2 test for categorical data. For each of the 4 parameters (SBP mean, SBP-CV, HR mean, and HR-CV), rates of cognitive dysfunction, decline, and deterioration were determined by quintiles and tested for differences using the χ 2 test. In addition, we developed a multivariate logistic regression model that included all 4 parameters of interest and the MMSE value at baseline and, in addition, all potential predictors of cognitive dysfunction, decline, and deterioration, particularly those displayed in Table. A stepwise selection procedure with P limits of 0.25 for entry into the model and 0.15 for stay in the model was applied; it was further checked whether the resulting optimal model was minimal in terms of Akaike's Information Criterion. The likelihood ratio test was used to check whether the addition of BP and HR parameters (as described above) significantly improve the predictive quality of the models; c-statistics are given as well. The association between SBP-CV and mean HR as continuous variables and cognitive outcomes was also analyzed nonparametrically with restricted cubic splines, allowing for potentially nonlinear relationship. 25 Additionally, as a sensitivity analysis, decline in MMSE was modeled as a continuous variable (reported in the online-only Data Supplement). Results are presented as odds ratios (OR) with 95% confidence intervals. All analyses were done using SAS version 9.2 (SAS Institute, NC).
Results
Correlation of Means, Standard Deviations, and CVs
The correlation between mean SBP and SBP SD was modest (r=0.28), as was the correlation between mean HR and HR SD (r=0.31). There was almost no correlation between mean SBP and SBP coefficient of variation (CV; r<0.01) and between mean H and HR-CV (r=0.05), and therefore, CV was chosen for further analysis instead of SD being less dependent on the mean. There was almost no correlation between mean SBP and mean HR (r=0.01), whereas the correlation between SBP-CV and HR-CV was small (r=0.15).
Demographics and Clinical Characteristics
Demographic data and clinical characteristics are presented for mean SBP, SBP-CV quintiles mean HR, and HR-CV quintiles (Table S1 in the online-only Data Supplement). Table S1 also contains a column for those 6953 patients who could not be included in the analysis. Because of the big sample size, most of the variables and characteristics were significantly different between quintiles, but the relevance of these (partly small) differences is unsure. As expected, there were some differences with cardiovascular medication, for example beta blockers were used more often at low HR. There were also some differences between the patients included in this analysis and the remaining patients of ONTARGET and TRANSCEND. Some of these differences were as a result of the selection of patients with MMSE >24 at study entry; excluding patients with preexisting cognitive dysfunction mainly affected patients with older age, less advanced formal education, less physical activity, black ethnicity, and worse kidney function. In line with the higher age of the excluded patients, means of SBP/HR and CVs were also slightly higher.
Proportions of Cognitive Dysfunction, Decline, and Deterioration by SBP Mean and CV
Cognitive dysfunction was observed in 1857 patients (7.6%) and cognitive decline in 1176 patients (4.8%); 1017 patients (4.1%) fulfilled the criteria for both end points. Regarding mean SBP (Figure 2A , left), incident cognitive dysfunction increased from 6.0% in the lowest to 9.4% in the highest quintile (P<0.0001). Cognitive decline (middle) ranged from 4.0% in the lowest to 5.7% in the highest quintile (P=0.0012). For the quintiles of SBP-CV ( Figure 2B ), cognitive dysfunction rates increased from 6.3% in the lowest to 10.2% in the highest quintile (P<0.0001). Cognitive decline rates ranged from 4.1% in the lowest to 6.4% in the highest quintile (P<0.0001; Figure 2B ). Similar results were obtained for cognitive deterioration (right; 7.4%-11.2% for mean SBP [P<0.0001] and 7.8%-12.1% for SBP-CV [P<0.0001], respectively).
Proportions of Cognitive Dysfunction, Decline, and Deterioration by HR Mean and CV
Regarding mean HR, incident cognitive dysfunction ( Figure 2C , left) increased from 5.6% in the lowest to 9.1% in the highest quintile (P<0.0001). Cognitive decline ( Figure 2C , middle) ranged from 3.4% in the lowest to 5.6% in the highest quintile (P<0.0001), with similar results for cognitive deterioration (6.8%-11.0%, right). For the quintiles of HR-CV ( Figure 2D ), cognitive dysfunction rates (left) ranged from 6.9% in the second (ie, lowest rate) to 8.5% in the highest quintile (P=0.027). Cognitive decline (middle) rates were evaluated from 4.0% to 5.4% in the fifth quintile of HR-CV (P=0.0098; Figure 2D ). Cognitive deterioration showed similar results (right).
Multivariate Model With Adjustment for Confounders
With respect to the incidence of cognitive dysfunction, SBP-CV (P=0.0030) and mean HR (P=0.0008) remained to be significant predictors after adjusting. The confounders, such as MMSE, at baseline, DBP-CV, age, body mass index, estimated glomerular filtration rate, sex, ethnicity, physical activity, formal education, alcohol consumption, history of stroke and new stroke during study conduct, history of diabetes mellitus, and new diabetes mellitus during study conduct, as well as concomitant medication with aspirin, beta blockers, diuretics, nitrates, statins, and hypoglycemics are given in Table. Compared with the lowest SBP-CV quintile (reference), the OR for having cognitive dysfunction was 1.32 (95% CI, 1.10-1.58; P=0.0029) in the highest quintile ( Figure 3A , left). When comparing the highest mean HR quintile to the lowest, the OR was 1.40 (1.18-1.66; P<0.0001; Figure 3B, The ORs for all confounders that remained in the model after the selection procedure are presented in Table, A.
Mean HR (P=0.0002; Figure 3B ) also was an independent predictor for cognitive dysfunction (left), decline (middle), and deterioration (right) after adjusting for the other parameters and all confounders. For mean HR, the upper 3 quintiles had significantly higher odds compared with the referent quintile, but with no apparent differences among these 3 quintiles were seen. Patients with higher MMSE baseline values had a greater chance for decline (OR, 1.07 [1.03-1.11] per unit). The ORs for all other factors in the model are presented in Table, B. Similar results were obtained for cognitive deterioration (Table, C; Figure 3 , right). The nonlinear relationship between SBP-CV as a continuous variable and the risk of cognitive outcomes (as a result of modeling with cubic splines) is shown in Figure 4A . A similar nonlinear relationship was observed with mean HR as shown in Figure 4B . 
Interaction With Stroke
No apparent heterogeneity in the effects of SBP-CV and mean HR on cognitive dysfunction, decline, and deterioration was seen in patients with or without previous stroke (before or during the studies [P values for test on interaction 0.61 for SBP-CV, 0.35 for mean HR on cognitive dysfunction, 0.76 for SBP-CV, 0.097 for mean HR for cognitive decline, and 0.62 for SBP-CV, 0.29 for mean HR for cognitive deterioration]).
Thus, the effects of high SBP variation and high mean HR apply similarly to patients with and without stroke.
Interaction With Atrial Fibrillation
No apparent heterogeneity in the effects of SBP-CV and mean HR on cognitive dysfunction and decline was seen in patients with or without atrial fibrillation (before or during the studies [P values for test on interaction 0.40 for SBP-CV, 0.43 for mean HR on cognitive dysfunction, 0.31 for SBP-CV, 0.11 for mean HR for cognitive decline]). Thus, the effects of high SBP variation and high mean HR apply similarly to patients with and without atrial fibrillation. Only for the association between mean HR and cognitive deterioration, there is some indication (P=0.042) for a heterogeneous effect; the detrimental effect of higher mean HR seems to be confined to patients without atrial fibrillation.
Interaction With Ethnicity
No heterogeneity in the effects of SBP-CV and mean HR was seen in patients with different ethnicities on cognitive dysfunction (P -values for test on interaction 0.91 for SBP-CV, 0.22 for mean HR) and of SBP-CV on cognitive decline (P=0. 44) and cognitive deterioration (P=0.99). However, the effect of mean HR on cognitive decline and deterioration seems to be differential between ethnicities (P=0.025 for decline, P=0.022 for deterioration); the detrimental effect of high mean HR is evident only in whites and Asians, whereas no effect is seen in blacks and patients of other ethnic origin.
Interaction of Blood Pressure Variation and Mean HR on Cognitive Function
To test whether there is any interaction between SBP-CV and mean HR, the respective interaction term was added to the multivariate model, which resulted from the model selection process described above. It turned out that no apparent interaction was present (P=0.55 for new cognitive dysfunction, P=0.11 for cognitive decline, P=0.70 for cognitive deterioration). The additivity in the detrimental effect of high SBP-CV and high mean HR is shown in Figure 5 , which shows ORs for combination of quintiles with the combination of first quintiles as reference for cognitive dysfunction (A), decline (B), and deterioration (C). Patients in the highest quintiles for each parameter show an OR of 1.85 (1.44-2.38) for cognitive dysfunction; for cognitive decline, the maximum OR is seen in Figure 3 . Development of cognitive dysfunction (left), cognitive decline (middle), and cognitive deterioration (right) according to systolic blood pressure coefficient of variation (CV; A) and mean heart rate (B) quintiles. Odds ratios of systolic blood pressure CV and mean heart rate quintiles were adjusted for mini mental state examination (MMSE) at baseline, diastolic blood pressure variation, age, body mass index, estimated glomerular filtration rate (Modification of Diet in Renal Disease [MDRD]), sex, ethnicity, physical activity, formal education, alcohol consumption, history of stroke and stroke during study conduct, history of diabetes mellitus and new diabetes mellitus during study conduct, and concomitant medications with aspirin, beta blockers, diuretics, nitrates, statins, and hypoglycemics as significant parameters, as selected in a stepwise selection procedure to identify the best multivariate logistic regression model. 
Sensitivity Analyses
When the analyses described above are run in the subset of patients with ≥3 visits subsequent the 6 week visit (n=24 365), the results are essentially the same. This has been done to reflect the possibility that SBP variation might be induced by BP reduction in the beginning of the trials. Further, in a linear model with (continuous) reduction in MMSE per year as dependent variable and the same variables, which were included in the logistic regression models described above, Figure 4 . Development of cognitive dysfunction (left), cognitive decline (middle), and cognitive deterioration (right) according to systolic blood pressure coefficient of variation (SBP-CV; A) and mean heart rate (B) as continuous variables. Odds ratios calculated based on logistic regression with restricted cubic splines (SBP-CV reference, 6%; mean heart rate reference, 60 bpm; gray area is 95% confidence band). as independent variables, the significant effect of SBP-CV (P<0.0001) and mean HR (P=0.0018) as well as the effects of the main predictors (baseline MMSE, age, education, and stroke) was confirmed (cf. Table S3 ). We also explored whether our results were dependent on the definition of cut-offs, for example, 25 points for MMSE at study end and 1 point for yearly reduction. Figure S1 shows that the upper quintiles of SBP-CV and mean HR show consistently higher cumulative percentages of patients being <27 at final MMSE ( Figure S1A and 1C) and also higher cumulative percentages of patients with yearly reductions in MMSE independent of its magnitude ( Figure S1B and 1D) . Thus, the effects demonstrated are not dependent on the specific choices of cut-offs, and similar effects would have been shown if cut-offs were different.
Discussion
Cardiovascular risk factors are the driving force in the development of cognitive dysfunction, [26] [27] [28] including Alzheimer's disease, 29, 30 leading to increased prevalence of dementia in the aging population. Herein, we report that SBP-CV and mean HR are related independently to cognitive decline as judged from the MMSE score by a decline ≥5 points, incident cognitive dysfunction defined as clinically relevant cognitive dysfunction to the MMSE score ≤24, and cognitive deterioration as drop in MMSE by ≥1 point per year or decline to ≤24 points).
The present analysis investigated the association of SBP and HR on incident cognitive dysfunction, cognitive decline, and cognitive deterioration. Many studies were conducted to identify the association of cardiovascular risk with SBP or HR by using a single measurement of SBP or HR. However, over time, SBP or HR as risk markers may vary and can place patients into different risk groups. Time varying statistical analyses have been used to analyze outcomes by Kaplan-Meier analyses for the shift of patients from one to another risk group, 31 an approach which was used to study the effects of SBP on clinical outcomes in the ONTARGET trial. 32 Herein, we have used multiple readings of HR and SBP for a given patient and averaged values when the number of visits exceeded 2 and determined mean SBP and mean HR over 10.7±2.2 visits. There was no or only a modest association of mean SBP and mean HR with the variation parameter, indicating that mean and CV are independent of each other. The data were collected over multiple visits and thereby giving a better integration of the total load of hemodynamic risk markers.
Blood Pressure Mean and Blood Pressure Variability
SBP was associated with cognitive dysfunction, cognitive decline, and cognitive deterioration, but after adjusting for confounders, the effect was not independent of traditional cardiovascular risk factors. The blood pressure hypothesis has been questioned before because variation, stability, and episodic signs of hypertension may be of greater importance in producing cardiovascular outcomes. 33 Accordingly, visit to visit variation of SBP was shown to predict the occurrence of stroke in hypertensive individuals, 34 as well as all-cause mortality in the general population 35 and was associated with microbleeds and white matter lesions in patients after an ischemic stroke. 36 Although associations of blood pressure with cognitive decline are convincing, 1,2,37 secondary analyses of cardiovascular trials aiming to investigate cognitive decline after blood pressure lowering have been inconsistent. The Syst-Eur trial included 2418 patients and was terminated prematurely as a result of significant differences in the incidence of stroke, leading to a short follow-up of only 2 years. 38 Dementia incidence was reduced and there was no significant change of MMSE, but there was a decline in the control group with decreasing diastolic blood pressure. 38 In patients with prior stroke or transitory ischemic attack, the Perindopril Protection Against Recurrent Stroke Study (PROGRESS) showed in 6105 randomized patients (with 48% being hypertensive) after follow-up of 3.5 years a relative risk reduction by 19% of incident dementia or cognitive decline defined as a MMSE reduction of ≥3 points, but only in patients with a recurrent stroke. 39 In contrast, Systolic Hypertension in the Elderly Program, the unblinded Medical Research Council's Trial on Hypertension in Older Adults, Hypertension in the Very Elderly Trial, and Study on Cognition and Prognosis in the Elderly showed trends but no significant effects of hypertensive therapies on cognitive function. [38] [39] [40] [41] [42] [43] Also treatment with RAS-inhibitors and non-RAS inhibitors showed no difference in patients after stroke (Prevention Regimen for Effectively Avoiding Second Strokes [PRoFESS]) 44 or in high risk patients of ONTARGET and TRANSCEND. 24 Interestingly, the association of SBP variation to stroke 7 or cerebral lesions 36 has not been investigated in cardiovascular intervention trials in high risk patients, except in one study on 201 elderly hypertensive individuals in Japan. 16 Because observational studies never proof causality and, in addition, drugs might act differently on SBP variation, 33, 34 intervention trials in high risk patients ought to prospectively investigate pharmacological interventions on SBP variation and outcomes. In a study on low risk hypertensives, in-trial mean BP was more predictive than SBP-CV. 45 It is open to speculation whether variation of blood pressure over time is caused by instable blood pressure regulation adding to the risk of plaque instability.
Heart Rate
In addition to blood pressure, HR has been identified to be associated with cardiovascular outcomes in patients with hypertension, 8 myocardial infarction, 9 and heart failure. 11 Reduction of clinical events by HR reduction with the If-channel inhibitor ivabradine, qualifying HR as a modifiable risk factor and not only as a risk marker, 10 has only been shown in heart failure. 46 In experimental animals after psychosocial stress, pharmacological HR reduction reduces stroke size.
14 In patients after stroke, cognitive decline was accelerated in patients with a HR >67 bpm and was, furthermore, associated with mortality, including cardiovascular mortality, but not recurrent stroke rates. 15 These findings suggest that stroke quality, for example, reduction in stroke size rather than a reduction of second strokes, might occur at low HR. 46 Thus, the findings in the PRoFESS trial 15 on patients after a previous stroke can be extended to patients without prior strokes because there was no significant interaction of HR risk relationship in patients with or without stroke in this analysis. Therefore, high HR may be a new risk marker of cognitive dysfunction and incident dementia in high risk patients with prevalent cardiovascular disease. It is tempting to speculate whether HR reduction by pharmacological interventions might reduce risk and delay cognitive dysfunction because in animals with by guest on April 29, 2017 http://hyper.ahajournals.org/ Downloaded from atherosclerosis, HR reduction has a strong protective effects on plaque formation, 47,48 promotes collateral growth, 49 protects endothelial function, and prevents erectile dysfunction, 50 an association which was also observed in humans.
51 Therefore, HR reduction should be tested in individuals with high risk for cognitive decline, for example after a stroke. Variation of HR was not shown to be of predictive value for cognitive decline or function, and this might be as a result of variability in office conditions where HR is taken.
Autonomic Regulation in Cognitive Impairment
Changes of HR and blood pressure relation have been observed in patients with dementia. In patients with Alzheimer's dementia, a higher HR was observed compared with controls.
52-54 Baroreflex function is impaired in Alzheimer dementia, 52 which might contribute to hypotensive syndromes 54 and enhanced postural blood pressure drops with subsequently impaired cortical perfusion.
53 Therefore, autonomic regulation resulting in higher blood pressure variation, greater HR, and its variability caused by central autonomic dysregulation might be mechanisms contributing to these findings.
Limitations and Strengths
This analysis is a retrospective exploratory analysis of randomized trials with neutral outcomes. Therefore, the allocation of individuals was not subject to randomization. However, this is the largest database in patients with high cardiovascular risk and long follow-up with an average of >10 visits. Furthermore, this is the first study investigating the association of variation of SBP over time with mean HR on incident cognitive decline and incident cognitive dysfunction. The strength is the availability of these measurements in >10 visits, providing a good integration of HRs over the whole study period. This analysis is confined to patients in sinus rhythm because atrial fibrillation per se is associated with cognitive dysfunction in this cohort. 55 Moreover, in ONTARGET and TRANSCEND, blood pressure was rather well controlled, and the results could have been different in patients with uncontrolled or even resistant hypertension. However, TRANSCEND and ONTARGET are trials on high risk patients on contemporary treatments for cardiovascular protection, in whom, on top of proven treatments, SBP-CV and mean HR show significant associations with cognitive function and incident impairment of cognition.
Conclusion
This study demonstrates that long-term SBP variations and mean HR levels are associated with the development of cognitive dysfunction, decline, and deterioration in high risk patients with atherosclerosis or after stroke or high-risk diabetes mellitus.
Perspectives
The secondary analysis of ONTARGET investigated the SBP variation and HR on new onset of cognitive decline, dysfunction, and deterioration in a large population of patients at high cardiovascular risk. HR and blood pressure variation may be considered markers of cognitive dysfunction in this patient population. HR and blood pressure variation might be important to judge the future risk of cognitive dysfunction. It should be incorporated in the clinical judgment of these patients. The study shows that SBP and mean HR are associated with cognitive dysfunction, with both parameters acting synergistically on this pathology. They should be incorporated in the work up of cardiovascular high risk patients. Studies on HR reduction and smoothening of SBP profiles are warranted.
Sources of Funding
Ongoing What Is New?
• The secondary analysis of Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial investigated the systolic blood pressure variation and heart rate on new onset of cognitive decline, dysfunction, and deterioration in a large population of patients at high cardiovascular risk.
• Heart rate and blood pressure variation may be considered as markers of cognitive dysfunction in this patient population.
What Is Relevant?
• Heart rate and blood pressure variation might be important to judge the future risk of cognitive dysfunction. It should be incorporated in the clinical judgment of these patients.
Summary
The study shows that systolic blood pressure and mean heart rate are associated with cognitive dysfunction, with both parameters acting synergistically on this pathology. They should be incorporated in the work up of cardiovascular high risk patients. Studies on heart rate reduction and smoothening of systolic blood pressure profiles are warranted. 
